BriaCell Announces Presentation and Abstract Publication at 2020 American Society of Clinical Oncology (ASCO) Meeting
May 14 2020 - 6:30AM
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”)
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, announces the publication of its abstract in the ASCO
Meeting Library — available in the Journal of Clinical Oncology by
May 26, 2020. The Company will present at the 2020 ASCO Annual
Meeting, a virtual event held during the dates of the originally
planned in-person Annual Meeting (May 29-June 2, 2020). The ASCO
Annual Meeting represents the world’s largest gathering of oncology
physicians, biotechnology executives, researchers, and investment
analysts to discuss cutting-edge clinical research and therapeutics
in oncology.
Dr. Bill Williams, BriaCell’s President &
CEO, and Dr. Charles Wiseman, BriaCell’s Scientific Founder and
Director, will present clinical data and pathological findings from
the Phase I/IIa studies of Bria-IMT™ alone or in combination with
checkpoint inhibitors in advanced breast cancer patients.
The
abstracts published in advance of the ASCO meeting which were made
available yesterday on the ASCO Meeting Library, and will
be available in the Journal of Clinical Oncology by May 26,
2020. Updated and additional
patient data from these trials will be presented at
ASCO.
The details of BriaCell’s ASCO poster are as follows:
Abstract Title: Breast cancer grade and
clinical benefit in patients with advanced breast cancer treated
with an engineered whole tumor cell-targeted immunotherapy alone or
in combination with checkpoint inhibition.Session
Title: Developmental Therapeutics—Immunotherapy
Session Type: Poster
SessionDate: Friday, May 29, 2020
Time: 8:00 AM - 11:00 AM CST
Location: Virtual meetingTemporary
Abstract Submission ID: 306433Abstract Number for
Publication: 3033Poster Board
#: 97Role
Responsibilities: PresenterPrimary
Track: Developmental
Therapeutics—Immunotherapy
Following the presentation, a copy of the poster
will be posted
on https://briacell.com/novel-technology/scientific-publications/.
About American Society of Clinical Oncology (ASCO)
Conference
Founded in 1964, ASCO is the world’s leading
professional organization for physicians, oncology professionals,
and research scientists in the field of oncology. ASCO’s Mission
over the years has been to conquering cancer through research,
education, and promotion of the highest quality patient care.
ASCO’s Annual meeting represents the world’s
largest gathering of oncology physicians, biotechnology executives,
researchers, patient advocates, and investment analysts to discuss
cutting-edge clinical research and therapeutics in oncology, and to
gain insights for improving cancer care.
For additional information on the 2020 ASCO’s
Annual meeting, please visit https://www.asco.org/.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to known
and unknown risks relevant to the Company in particular and to the
biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but
are not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024